Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1901-1908

  Jacobs, Michael R ^a,b   Bajaksouzian, Saralee ^a   Zilles, Anne ^a   Lin, Gengrong ^c   Pankuch, Glenn A ^c   Appelbaum, Peter C ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFIXIME; CEFPROZIL; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; LORACARBEF;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0032854834     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1901     Document Type: Article

References (42)

1. Barry, A. L., and P. C. Fuchs. 1995. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob. Agents Chemother. 39:238-240.
2. Barry, A. L., M. A. Pfaller, P. C. Fuchs, and R. R. Packer. 1994. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob. Agents Chemother. 38:2419-2425.
3. Barry, A. L. 1995. Antimicrobial agents for community-acquired respiratory tract infections. Infection 23(Suppl. 2):S59-S63. (Discussion, S64.)
4. Bartlett, J. G. 1997. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin. Respir. Infect. 12:329-333.
5. Black, S. B., H. R. Shinefield, and The Kaiser Permanente Vaccine Study Group. 1992. Immunization with oligosaccharide conjugate Haemophilus inftuenzae type b (HbOC) vaccine on a large HMO population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. Pediatr. Infect. Dis. J. 11:610-613.
6. Bradley, J. S., and J. D. Connor. 1991. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to β-lactam antibiotics. Pediatr. Infect. Dis. J. 10:871-872.
7. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
8. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
9. Dagan, R., O. Abramson, E. Leibovitz, D. Greenberg, R. Lang, S. Goshen, P. Vagupsky, A. Leiberman, and D. M. Fliss. 1997. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J. Infect. Dis. 176:1253-1259.
10. Dagan, R., O. Abramson, E. Leibovitz, R. Lang, S. Goshen, D. Greenberg, P. Yagupsy, A. Leiberman, and D. M. Fliss. 1996. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr. Infect. Dis. J. 15:980-985.
11. Dagan, R., L. Piglansky, P. Vagupsky, D. M. Fliss, A. Leiberman, and E. Leibovitz. 1997. Bacteriologic response in acute otitis media (AOM): comparison between azilhromycin (AOM), (AZ), cefaclor (CEC) and amoxicillin (AMOX), abstr. K-103, p. 346. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Doern, G. V., A. B. Brueggemann, G. Pierce, H. P. Holley, Jr., and A. Rauch. 1997. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. 41:292-297.
13. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
14. Doern, G. V., J. H. Jorgensen, C. Thornsberry, D. A. Preston, T. Tubert, J. S. Redding, and L. A. Maher. 1988. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob. Agents Chemother. 32:180-185.
15. Doern, G. V. 1996. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative study. J. Antimicrob. Chemother. 38(Suppl. A):59-69.
16. Dowell, S. F., S. M. Marcy, W. R. Phillips, M. A. Gerber, and B. Schwartz. 1998. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 101:163-165.
17. Dowell, S. F., J. C. Butler, G. S. Giebink, M. R. Jacobs, D. Jernigan, D. M. Musher, A. Rakowsky, and B. Schwartz. 1999. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J. 18:1-9.
18. Drusano, G. L., and W. A. Craig. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 9(Suppl. 3):38-44.
19. Drusano, G. L., and F. W. Goldstein. 1996. Relevance of the Alexander Project: pharmacodynamic considerations. J. Antimicrob. Chemother. 38 (Suppl. A):141-154.
20. Green, M., and E. R. Wald. 1996. Emerging resistance to antibiotics: impact on respiratoiy infections in the out-patient setting. Ann. Allergy Asthma Immunol. 77:167-173.
21. Jackson, M. A., V. F. Burry, L. C. Olson, S. E. Duthie, and G. L. Kearns. 1996. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. J. 15:1049-1051.
22. Jacobs, M. R. 1999. Assessing the quality of the Alexander Project. J. Chemother. 11:26-34.
23. Jacobs, M. R., and P. C. Appelhaum. 1995. Antibiotic-resistant pneumococci. Rev. Med. Microbiol. 6:77-93.
24. Jacobs, M. R., and S. Bajaksouzian. 1997. Microbiologic evaluation of contemporary Haemophilus influenzae isolates having elevated MICs to amoxicillin-clavulanic acid. Diagn. Microbiol. Infect. Dis. 28:105-112.
25. Jones, R. N., M. R. Jacobs, J. A. Washington, and M. A. Pfaller. 1997. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagn. Microbiol. Infect. Dis. 27:75-83.
26. Khan, W., S. Ross, W. Rodriguez, G. Controni, and A. K. Saz. 1974. Haemophilus influenzae type b resistant to ampicillin: a report of two cases. JAMA 229:298-301.
27. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
28. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial susceptibility testing. Sixth information supplement M100-S7. National Committee for Clinical Laboratory Standards, Villanova, Pa.
29. Nightingale, C. H. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr. Infect. Dis. J. 16:438-443.
30. Pelton, S. I. 1996. Defining resistance: breakpoints and beyond implications for pediatric respiratory infection. Diagn. Microbiol. Infect. Dis. 25:195-199.
31. PMSI Scott-Levin, Inc. 1997. Physician drug and diagnosis audit (PDDA). PMSI Scott-Levin, Inc., Newtown, Pa.
32. Reid, R., Jr., J. S. Bradley, and J. Hindler. 1995. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr. Infect. Dis. J. 14:1104-1105.
33. Rittenhouse, S. F., L. A. Miller, R. L. Kaplan, G. H. Mosely, and J. A. Poupard. 1995. A survey of β-lactamase-producing Haemophilus influenzae. Diagn. Microbiol. Infect. Dis. 21:223-225.
34. Roberts, D. E., A. Ingold, S. V. Want, and J. R. May. 1974. Osmotically stable L-forms of Haemophilus influenzae and their significance in testing sensitivity to penicillins. J. Clin. Pathol. 27:560-564.
35. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
36. Rolinson, G. N. 1994. A review of the microbiology of amoxicillin-clavulanic acid over the 15-year period 1978-1993. J. Chemother. 6:283-318.
37. Rosenfeld, R. M. 1996. An evidence-based approach to treating otitis media. 1996. Pediatr. Clin. N. Am. 430:1165-1181.
38. Sloas, M. M., F. F. Barrett, P. J. Chesney, B. K. English, B. C. Hill, F. C. Tenover, and R. J. Leggiadro. 1992. Cephalosporin treatment failure in penicillin-and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 11:662-666.
39. Sykes, R. B., A. Griffiths, and D. M. Ryan. 1977. Comparative activity of ampicillin and cefuroxime against three types of Haemophilus influenzae. Antimicrob. Agents Chemother. 11:599-604.
40. Thornsberry, C., P. Oglivie, J. Kahn, and Y. Mauritz. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season, Diagn. Microbiol. Infect. Dis. 29:249-257.
41. Tomeh, M. O., S. E. Starr, J. E. McGowan, Jr., P. M. Terry, and A. J. Nahamias. 1974. Ampicillin-resistant Haemophilus influenzae type b infection. JAMA 229:295-297.
42. Vergis, E. N., and V. L. Yu. 1997. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Semin. Respir. Infect. 12:322-328.